Stockscreener 앱 받기
0.6246
4.97%
0.0296
시장 영업 전:
.62
-0.0046
-0.74%
Femasys Inc 주식(FEMY)의 최신 뉴스
How Femasys Inc. stock reacts to inflationary pressures2026 world cup usa national team group stage goalkeepers counter attacking expert forecast guide - ulpravda.ru
Earnings Beat: Will MARZ stock keep high P E multiples2025 Biggest Moves & Pattern Based Trade Signal System - moha.gov.vn
Femasys gains UK approval for women's health products - MSN
Market Leaders: How strong is Femasys Inc stock balance sheetQuarterly Earnings Summary & AI Forecast for Swing Trade Picks - moha.gov.vn
User | theeveningleader.comFemasys Inc.Common Stock (Nasdaq:FEMY) Stock Quote - FinancialContent
Femasys files for at-the-market offering of up to $9.8 million in common stock - Investing.com India
Femasys Launches At-the-Market Common Stock Offering - TipRanks
Femasys files for at-the-market offering of up to $9.8 million in common stock By Investing.com - Investing.com South Africa
Femasys Inc Files Prospectus for Stock Offering - TradingView — Track All Markets
Suwanee company Femasys Inc. gets FDA approval for diagnostic device - The Business Journals
Will Femasys Inc. stock maintain growth story2025 Market Sentiment & Target Return Focused Stock Picks - Улправда
Contemporary OB/GYN week in review: FemVue clearance, flibanserin approval, and more - Contemporary OB/GYN
Swing Trade: Why Femasys Inc. stock is a must watch in 20252025 Geopolitical Influence & Accurate Intraday Trading Signals - Улправда
What momentum indicators show for Femasys Inc. stockMarket Sentiment Review & Risk Managed Trade Strategies - Bölüm Sonu Canavarı
Why Femasys Inc. stock is rated strong buyJuly 2025 Momentum & Real-Time Volume Spike Alerts - Улправда
Femasys receives FDA clearance for FemVue Controlled diagnostic device By Investing.com - Investing.com Australia
How interest rate cuts could boost Femasys Inc. stockMarket Growth Review & Technical Entry and Exit Tips - Bölüm Sonu Canavarı
How strong is Femasys Inc. stock balance sheet2025 Trading Recap & Consistent Profit Focused Trading Strategies - DonanımHaber
Why Femasys Inc. stock is a must watch in 20252025 Market Sentiment & Growth Oriented Trade Recommendations - Улправда
What analyst consensus says on Femasys Inc. stockJuly 2025 Action & AI Powered Market Trend Analysis - DonanımHaber
Femasys Earnings Notes - Trefis
PharmaCyte Biotech (Nasdaq: PMCB) reports Q2 loss and details QCLS, Femasys deals - Stock Titan
Femasys Inc. Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - marketscreener.com
FDA clears FemVue Controlled for in-office tubal assessment - Contemporary OB/GYN
Femasys secures U.S. FDA clearance for next-generation Femvue diagnostic device - marketscreener.com
Femasys Gains FDA Clearance for FemVue Diagnostic Device - TipRanks
Femasys gains FDA clearance for FemVue diagnostic device - MSN
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - The Manila Times
Femasys Inc Secures FDA Clearance for FemVue Diagnostic Device - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) secures FDA clearance for next-generation FemVue diagnostic - Stock Titan
Femasys receives FDA clearance for FemVue Controlled diagnostic device - Investing.com
Femasys Inc. Receives FDA Clearance for Innovative FemVue Controlled Device to Enhance Fallopian Tube Evaluation and Workflow Efficiency - Quiver Quantitative
New device could make fallopian tube testing simpler for fertility care - Stock Titan
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
Femasys Secures Major Order for FemBloc Launch - MSN
Femasys Receives FDA Approval for FemBloc Trial - MSN
FDA Approves Final Trial Phase for Femasys’ Permanent Birth Control Product - Medical Product Outsourcing
PharmaCyte’s Successful Stake Earns them Millions - StocksToTrade
PharmaCyte Boosts Financial Position with Femasys Stake Sale - timothysykes.com
Femasys Inc Stock Analysis and ForecastTechnical Breakout Signals & Minimal Capital Trading - earlytimes.in
CapEx per share of Femasys Inc. – NASDAQ:FEMY - TradingView
Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen - MarketBeat
PharmaCyte Biotech stock surges following profitable exit from Femasys investment - MSN
Energy Moves: Why Femasys Inc. stock is a must watch in 2025Weekly Investment Report & Community Verified Trade Alerts - moha.gov.vn
PharmaCyte Biotech sells Femasys stake, boosts cash position to $20 million - Investing.com Nigeria
PharmaCyte Biotech stock soars after successful Femasys stake sale By Investing.com - Investing.com Australia
0.51%
1.30%
자본화:
|
볼륨(24시간):